Philippe Peltier
MANAGING PARTNER
Management
Kurma Partners
Denmark
Biography
MS in molecular biology (Paris 7 University) and MS in Finance (ESSEC). He was previously a Partner with Auriga Partners from 1999 and 2015 and conducted several investments in Life Sciences. Philippe served on the board of several portfolio companies including Genocea Biosciences (listed on Nasdaq), Implanet (listed on Euronext), Novagali Pharma (listed on Euronext and acquired by Santen), Innate Pharma (listed on Euronext), Tigenix (listed on Euronext), Spine Next (acquired by Abbott Spine), Alantos (acquired by Amgen). Philippe joined Kurma in July 2015. He is also a board member of DNA script (France), APD (France), Damae (France) and Sensome (France).
Research Interest
Biomedical science, Business management, Molecular Biology
